Paul Strumph, MD was appointed Chief Medical Officer of Metavant Sciences, Inc., in August, 2018. In his most recent position at Lexicon Pharmaceuticals, he served as Vice President, Clinical Development, where he led the global clinical development team from early phase II work through successful MAA and NDA filings of sotagliflozin, a first in class dual SGLT1 and SGLT2 inhibitor discovered and developed by Lexicon as an oral adjunct to insulin therapy in type 1 diabetes. Paul has assumed phase I to IV clinical development roles of increasing programmatic and strategic responsibility at large and small pharma including GlaxoSmithKline, Merck KGaA/EMD, and Bristol- Myers Squibb & Co. He served as Vice President, Therapeutic Strategy Head of the Cardiovascular and Metabolic Therapy Area, Chair of the Diabetes Center of Excellence, and North America Regional Chief Medical Officer at Quintiles.
Paul has over 30 years of experience in Endocrinology and Diabetes, including leadership roles at the non-profit Juvenile Diabetes Research Foundation (JDRF) as Chief Medical Officer. Paul received his undergraduate degree from Wesleyan University, his M.D. with distinction in research from the University of Rochester, and completed residency training in Combined Internal Medicine and Pediatrics at Emory University. He completed two fellowships: Adult Endocrinology Diabetes and Metabolism at the University of Pittsburgh Medical Center as well as Pediatric Endocrinology at the Children’s Hospital of Pittsburgh. Paul is one of a handful of Endocrinologists to be a Diplomate of 2 specialty, and 2 subspecialty boards. He practiced Adult and Pediatric Endocrinology for 6 years, and served as a Clinical Associate Professor, UNC Departments of Internal Medicine and Pediatrics.